Fig. 3
From: Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma
IRF4 ASO and lenalidomide decrease ATLL tumor burden in vivo. On Day 0, NSG mice received an intraperitoneal injection of 10 million ATL-ED cells. Mice were treated with 12 doses of IRF4 ASO (n = 2), lenalidomide (n = 2), or PBS (n = 3) over 18 days. Mice were euthanized on day 18 and peripheral blood was collected. a Schematic of experimental design. b, c Representative flow cytometry data of human ATLL cells in the peripheral blood (hCD45 + hCD4 +) and quantitation of the flow data set. d Representative blood smears of each treatment group